Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income (loss)	$ 306,564	$ 77,781
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	295,259	72,863
Change in fair value of contingent consideration	30,676	45,707
Share-based compensation expense	151,209	160,853
Deferred taxes	95,771	385,915
Change in excess tax benefit from stock options	0	76,291
Unrealized Gain (Loss) on Derivatives and Commodity Contracts	10,666	769
Other	(921)	(1,837)
Changes in operating assets and liabilities
Accounts receivable	(129,875)	(90,952)
Inventories	(72,190)	(7,368)
Prepaid expenses and other assets	(119,897)	(80,015)
Accounts payable, accrued expenses and other liabilities	92,775	(147,108)
Deferred revenue	43,267	(8,557)
Net cash provided by operating activities	703,304	484,342
Cash flows from investing activities:
Purchases of available-for-sale securities	(655,974)	(372,537)
Proceeds from maturity or sale of available-for-sale securities	485,382	1,092,968
Purchases of trading securities	(6,173)	(12,249)
Proceeds from sale of trading securities	2,337	8,287
Purchases of property, plant and equipment	(225,995)	(206,224)
Payment for acquisition of business, net of cash acquired	0	(3,939,307)
Other	(1,135)	5,479
Net cash used in investing activities	(401,558)	(3,423,583)
Cash flows from financing activities:
Debt issuance costs	0	(45,492)
Proceeds from revolving credit facility	0	200,000
Proceeds from term loan	0	3,500,000
Payments on revolving credit facility	0	(200,000)
Payments on term loan	(175,000)	(57,500)
Equity issuance costs for shares issued in connection with acquisition of business	0	(4,053)
Change in excess tax benefit from stock options	0	(76,291)
Repurchase of common stock	(399,972)	(175,383)
Net proceeds from issuance of common stock under share-based compensation arrangements	27,760	50,824
Payments of contingent consideration	0	(50,000)
Proceeds from development related grants	0	26,000
Other	(5,325)	(1,718)
Net cash (used in) provided by financing activities	(552,537)	3,166,387
Effect of exchange rate changes on cash	2,669	(7,864)
Net change in cash and cash equivalents	(248,122)	219,282
Cash and cash equivalents at beginning of period	1,010,111	943,999
Cash and cash equivalents at end of period	761,989	1,163,281
Supplemental cash flow disclosures from investing and financing activities:
Common stock issued in acquisition of business	0	4,917,810
Capitalization of construction costs related to facility lease obligations	84,838	40,185
Accrued expenses for purchases of property, plant and equipment	$ 22,686	$ 25,165